# Nuformix advances NXP002 programme with £168,750 Placing

- Link: https://www.directorstalkinterviews.com/nuformix-advances-nxp002-programme-with-168750-placing/4121185199
- Published: 2025-01-30T07:27:04+00:00
- Author: Amilia Stone

**Nuformix plc **([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l)),
a pharmaceutical development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing, has announced a placing to raise gross proceeds of
£168,750 through the issue of 250,000,000 new ordinary shares of 0.05 pence each
in the capital of the Company at a price of 0.0675 pence per share.  The New Ordinary
Shares equate to approximately 17.6% of the Company’s currently issued share capital.

The net proceeds of the Placing will be used by the Company primarily to progress
ongoing partnering discussions for its NXP002 programme, an inhaled treatment for
idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), as
well as to provide funding for general corporate purposes.

CMC Markets UK Plc, trading as CMC CapX, acted as the Company’s sole placing agent
in respect of the Placing.

**Admission and Total Voting Rights**

The Placing has been conducted utilising the Directors existing authorities to allot
shares.  The New Ordinary Shares will rank _pari passu_ in all respects with the
existing ordinary shares.  The Placing is conditional, inter alia, on there being
no breach of the obligations under the Placing Agreement entered into between CMC
Markets and the Company prior to Admission, and admission of the New Ordinary Shares
to trading on the Main Market of the London Stock Exchange becoming effective.

Application will be made to the London Stock Exchange for the New Ordinary Shares
to be admitted to trading on the Main Market of the London Stock Exchange and the
Equity Shares (Transition) category the FCA Official List.  It is expected that 
Admission will become effective and that dealings in the New Ordinary Shares on 
the Main Market of the London Stock Exchange will commence on or around 5 February
2025.

Following Admission of the New Ordinary Shares, the total number of ordinary shares
in issue will be 1,669,309,368, each with one voting right.  Nuformix does not hold
any rights in treasury.  The total voting rights figure is therefore 1,669,309,368
and can be used by shareholders as the denominator for the calculations by which
they will determine whether they are required to notify their interest in, or a 
change of their interest in, the Company under the Disclosure Guidance and Transparency
Rules of the Financial Conduct Authority.

Share on:
